Q-omics provides the consensus-scored MMP26 profile across patient tissues and cancer cell-line models. MMP26 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MMP26 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MMP26 RNA expression shows 6,883 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where MMP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMP26 survival associations across molecular data types. MMP26 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMP26 RNA expression–survival associations across cancer types. High MMP26 expression shows unfavorable associations in KIRC, CESC, MESO and LIHC, but favorable associations in UCEC and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for MMP26 RNA expression.
This table summarizes MMP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MMP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMP26 shows lower tumor expression in STAD, ESCA and KIRC and higher tumor expression in KICH and PRAD. The KICH box plot shows higher MMP26 RNA expression in tumor versus normal tissue (log2 FC = +0.999, t-test p = .001).
This table shows molecular features associated with MMP26 in patient tissues and cancer cell lines. In patient samples, MMP26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MMP26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
